NCT00142155View on ClinicalTrials.gov

Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia

NACompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Waldenstrom's Macroglobulinemia
Interventions
DRUG

Rituximab

DRUG

monoclonal antibodies

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT00142155 - Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia | Biotech Hunter | Biotech Hunter